4 Medical Devices Behemoths to Buy Amid Extensive AI Applications

The growing demand for precision and personalized medicine is driving significant integration of artificial intelligence (AI) into medical devices, presenting compelling investment opportunities. Companies such as Boston Scientific (BSX), Johnson & Johnson (JNJ), GE HealthCare (GEHC), and Tempus AI (TEM) are highlighted for their robust AI applications across diagnostics, surgical robotics, and personalized treatment planning. These firms, particularly high-growth Tempus AI, are well-positioned to capitalize on this trend, with several exhibiting strong revenue and earnings growth projections as AI transforms healthcare delivery.

Analysis

The integration of artificial intelligence into medical devices is a significant secular growth trend, driven by the increasing demand for precision and personalized medicine. An analysis of four key players reveals distinct investment profiles within this theme. Tempus AI (TEM) stands out as a high-growth vehicle, with projected revenue and earnings growth of 81.1% and 55.7% respectively, focusing on AI-enabled precision medicine solutions for oncology and cardiology. Boston Scientific (BSX) also demonstrates a strong growth trajectory, with expected revenue and earnings increases of 18.3% and 18.7%, supported by successful AI-driven products like the HeartLogic diagnostic and a 2.4% upward revision in consensus earnings estimates over the last 30 days. In contrast, Johnson & Johnson (JNJ) represents a more stable, large-cap approach; while its MedTech division is advancing with platforms like the Ottava surgical robot, its overall corporate growth is more modest at 5.2% for revenue and 8.8% for earnings. GE HealthCare (GEHC) presents a unique case, with a significant 12.7% improvement in its consensus earnings estimate despite projecting tepid revenue growth of 3.5%, suggesting a potential margin expansion or operational efficiency story that may not be fully priced in. All four companies carry a Zacks Rank #2 (Buy), indicating a broadly positive analyst outlook across different segments of the AI-in-healthcare market.

Key Decisions for Investors

• Investors should consider exposure to the AI in MedTech theme, tailoring their selection based on risk appetite, with Tempus AI offering high-growth potential and Johnson & Johnson providing stable, large-cap exposure.
• For growth-focused portfolios, Boston Scientific and Tempus AI appear most compelling, given their double-digit projected growth rates and recent positive revisions to earnings estimates.
• GE HealthCare warrants closer examination, as the substantial 12.7% upward revision in its earnings consensus estimate suggests a potential catalyst or turnaround story that is not captured by its low single-digit top-line growth forecast.
• Monitor key product adoption milestones, such as the market penetration of BSX's Rhythm AI module and JNJ's Ottava robotic platform, as these will serve as critical validation points for their respective AI strategies and growth theses.